Core Viewpoint - Novo Nordisk's Kyinsu® (IcoSema) has received EU approval, combining weekly insulin with GLP-1 receptor agonist for better management of type 2 diabetes in adults [4][6]. Group 1: Product Overview - Kyinsu® integrates Icodec insulin for sustained blood sugar control and Semaglutide for weight management [7]. - The product allows for a single weekly injection, simplifying treatment with a maximum dosage of 350 units of Icodec and 1.0 mg of Semaglutide [7]. - Clinical trials involving over 2,500 adult type 2 diabetes patients demonstrate Kyinsu®'s efficacy in reducing HbA1c levels and achieving significant weight loss with lower hypoglycemia rates compared to daily insulin regimens [7]. Group 2: Industry Impact - The weekly injection format of IcoSema addresses the common delay in insulin therapy initiation among type 2 diabetes patients, where about 50% delay treatment for over two years, increasing complication risks [6]. - The design of Kyinsu® aims to enhance patient adherence to treatment and offers a new option for personalized therapy [6].